This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Satellos Bioscience Inc.
Announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration, along with parallel regulatory filings in the United Kingdom, Europe, Serbia and Australia, to initiate a Phase 2 clinical trial of SAT-3247 in ambulatory children with Duchenne muscular dystrophy (Duchenne or DMD). Satellos Bioscience Inc. shares T.MSCL are trading up $0.02 at $0.65.
